Abstract:Highlight • PU significantly reduced elevated SUA levels and protected the kidney and intestine of hyperuricemia mice. • PU improved the expression of UA transporters by ameliorating the MAPK/NF-κB signaling pathway in the kidney and intestine of hyperuricemia mice. • PU restored renal glycometabolism homeostasis in hyperuricemia mice. • PU ameliorated gut microbiota dysbiosis closely linked to inflammation and dysfunction of the intestine in hyperuricemia mice. Introduction It is estimated that 90% of hyperuricemia cases are attributed to the inability to excrete uric acid (UA). The two main organs in charge of excreting UA are the kidney (70%) and intestine (30%). Previous studies have reported that punicalagin (PU) could protect against kidney and intestinal damages, which makes it a potential candidate for alleviating hyperuricemia. However, the effects and deeper action mechanisms of PU for managing hyperuricemia are still unknown. Objective To investigate the effect and action mechanisms of PU for ameliorating hyperuricemia. Methods The effects and action mechanisms of PU on hyperuricemia were assessed using a hyperuricemia mice model. Phenotypic parameters, metabolomics analysis, and 16S rRNA sequencing were applied to explore the effect and fundamental action mechanisms inside the kidney and intestine of PU for improving hyperuricemia. Results PU administration significantly decreased elevated serum uric acid (SUA) levels in hyperuricemia mice, and effectively alleviated the kidney and intestinal damage caused by hyperuricemia. In the kidney, PU down-regulated the expression of UA resorption protein URAT1 and GLUT9, while up-regulating the expression of UA excretion protein ABCG2 and OAT1 as mediated via the activation of MAKP/NF-κB in hyperuricemia mice. Additionally, PU attenuated renal glycometabolism disorder, which contributed to improving kidney dysfunction and inflammation. Similarly, PU increased UA excretion protein expression via inhibiting MAKP/NF-κB activation in the intestine of hyperuricemia mice. Furthermore, PU restored gut microbiota dysbiosis in hyperuricemia mice. Conclusion This research revealed the ameliorating impacts of PU on hyperuricemia by restoring kidney and intestine damage in hyperuricemia mice, and to be considered for the development of nutraceuticals used as UA-lowering agent. Graphical abstract Schematic diagram illustrated the action mechanisms through which PU reduced UA level in hyperuricemia mice by protecting the kidney and intestine. Schematic diagram created using Figdraw ( www.figdraw.com ). Download : Download high-res image (227KB) Download : Download full-size image

Punicalagin Prevents Hepatic Steatosis Through Improving Lipid Homeostasis and Inflammation in Liver and Adipose Tissue and Modulating Gut Microbiota in Western Diet-Fed Mice.

Punicalagin Alleviates Renal Injury Via the Gut-Kidney Axis in High-Fat Diet-Induced Diabetic Mice.

Punicalagin Improves Hepatic Lipid Metabolism Via Modulation Of Oxidative Stress And Mitochondrial Biogenesis In Hyperlipidemic Mice

Pomegranate Fruit Pulp Polyphenols Reduce Diet-Induced Obesity with Modulation of Gut Microbiota in Mice.

A new way for punicalagin to alleviate insulin resistance: regulating gut microbiota and autophagy

Gut Microbiota-Mediated Modulation of Lipid Metabolism by Punicic Acid in Diet-Induced Hepatic Steatosis

Punicalagin Inhibits Palmitate Acid-induced Lipoapoptosis Through Inhibition of ER Stress, and Activation of SIRT1/Autophagy in HepG2 Cells

Mitochondrial Dysfunction in Obesity-Associated Nonalcoholic Fatty Liver Disease: the Protective Effects of Pomegranate with Its Active Component Punicalagin.

Punicalagin Alleviates Hypercholesterolemia in Mice Through Modulating Farnesoid X Receptor Signaling and Modulating Gut Microbiota

Punicalagin Protects against Diabetic Liver Injury by Upregulating Mitophagy and Antioxidant Enzyme Activities

Punicalagin Attenuates Endothelial Dysfunction by Activating FoxO1, a Pivotal Regulating Switch of Mitochondrial Biogenesis.

Punicalagin Reversed the Hepatic Injury of Tetrachloromethane by Antioxidation and Enhancement of Autophagy.

Punicalagin Relieves Lipotoxic Injuries on Pancreatic Β-Cells Via Regulating the Oxidative Stress and Endoplasmic Reticulum Stress-Mediated Apoptosis.

Punicalagin attenuates hyperuricemia via restoring hyperuricemia-induced renal and intestinal dysfunctions

Punicalagin Ameliorates Diabetic Liver Injury by Inhibiting Pyroptosis and Promoting Autophagy via Modulation of the FoxO1/TXNIP Signaling Pathway

A New Possible Mechanism by Which Punicalagin Protects Against Liver Injury Induced by Type 2 Diabetes Mellitus: Upregulation of Autophagy Via the Akt/FoxO3a Signaling Pathway

Punicalagin prevents the bone loss of diabetic mice induced by high‐fat diet via the metabolism of gut microbiota

PGC1 protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response

Punicalagin Attenuates Palmitate-Induced Lipotoxicity in HepG2 Cells by Activating the Keap1-Nrf2 Antioxidant Defense System.

Protective mechanism of punicalagin against endoplasmic reticulum stress in the liver of mice with type 2 diabetes mellitus

PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response.